Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored. wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants비강 오미크론 백신 부스터는 새로운 SARS-CoV-2 변이체에 대한 강력한 중화 항체 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] absence adjuvants administration antibody Antibody Response boost booster Bronchoalveolar lavage caused clinical trial composed COVID-19 COVID-19 pandemic current deaths delta variant described disease severity domain dose effective Elevation elicit evidenced FIVE fused human infection human infections humans IgA Immunity immunogen intranasal leads mice MOST mucosal nasal nasal protein vaccine booster Neutralizing activity neutralizing antibody Neutralizing antibody response omicron Omicron variant omicron variant. Protein Receptor binding domain reduce respiratory SARS-CoV-2 SARS-CoV-2 nucleoprotein SARS-CoV-2 spike SARS-CoV-2 transmission SARS-CoV-2 variant severity significantly single dose suggested the antibody response the disease vaccination Vaccine virus infection wild-type [DOI] 10.1080/22221751.2022.2053365 PMC 바로가기 [Article Type] Article
Antibody titers and neutralizing activity in cases of COVID-19 after a single dose of vaccinationArticle Published on 2022-12-012022-11-15 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 진단, [키워드] acute respiratory syndrome antibody Antibody titers coronavirus coronavirus disease Course COVID-19 Efficacy examined first vaccination immune response Infection Neutralizing activity Neutralizing titer onset of disease Patient SARS-CoV-2 shown single dose vaccination vaccination. [DOI] 10.1016/j.jiac.2022.08.026 PMC 바로가기
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccinationArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome addition adenoviral-vectored vaccine antibody AZD1222 binding antibody BNT162b2 booster booster vaccination Booster vaccine comparable Complete coronavirus Coronavirus 2019 COVID-19 demonstrated develop dose Effect enrolled enzyme-linked immunosorbent Heterologous highest immune evasion immune response Immunogenicity analysis individual induce interferon-γ Messenger RNA Mild moderate mRNA mRNA vaccine mRNA-1273 mutations NAb titer NAbs neutralization neutralize Neutralizing Neutralizing activity neutralizing antibody observé Omicron variant Omicron. overcome participant raise receive receiving reduction response Serious Adverse Events significant increase Spike protein T-cell activation T-cell Response T-cell responses vaccination Vaccine waning immunity was recorded were measured [DOI] 10.1002/jmv.28044 PMC 바로가기
Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome antibody asymptomatic infections benefit blood sample booster dose Clinical severity collected coronavirus coronavirus disease COVID-19 COVID-19 vaccination detectable dose evaluated Evidence first dose humoral humoral immune response Humoral immunity Humoral response inactivated Inactivated COVID-19 vaccine individual individuals infected individuals Infection median mild cases moderate multicenter NAb titer NAbs naïve individual naïve individuals natural infection Neutralizing Neutralizing activity neutralizing antibody omicron pan-immunoglobulins. participant prospective cohort study Protein receive recovered patient SARS-CoV-2 second dose seroconversion rate severity significantly single dose single vaccine the vaccine U/mL vaccination variant [DOI] 10.1002/jmv.28055 PMC 바로가기
A replication-competent smallpox vaccine LC16m8Δ-based COVID-19 vaccineArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome analysed antibody antibody titres BALB/c BALB/c mouse boost CD4 CD8 cellular cellular immunity coronavirus coronavirus disease COVID-19 COVID-19 vaccine Delta/B.1.617.2 variant of concern effective eight elicited emerging and re-Emerging coronaviruses glycoprotein homologous humoral Humoral immunity immunization Japanese LC16m8 less mice motif multifunctional neutralized Neutralizing activity patients with COVID-19 polybasic prime-boost immunization. provide recombinant replication-competent viral S-specific antibody S1/S2 cleavage site SARS-CoV-2 serum sample significantly lower Strains T-cell immune responses T-cell immunity T-cell Response the S protein Vaccine Vaccine development vaccine platform variant vector viral vectors virus Wuhan [DOI] 10.1080/22221751.2022.2122580 PMC 바로가기
Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection2003년 SARS-CoV 감염 이력이 있는 개인에서 비활성화된 SARS-CoV-2 백신 접종 후 광범위하고 지속적인 항체 반응Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] activity antibody Antibody Response Antigen Beta Delta dosage greater Heterologous heterologous immunization inactivated Inactivated vaccine individual naïve vaccinees neutralizing activities Neutralizing activity nucleoprotein omicron pseudovirus pseudoviruses RBD of SARS-CoV-2 receiving SARS-CoV SARS-CoV infection SARS-CoV-2 SARS-CoV-2 vaccine SARS-related coronaviruses second vaccination significantly higher suggested undetectable universal vaccine. vaccination Vaccine vaccinee vaccinees variant variants virus viruses were infected Wuhan [DOI] 10.1080/22221751.2022.2076613 PMC 바로가기 [Article Type] Article
Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domainSARS-CoV-2 S2 도메인에 대한 항체의 결합 및 중화 능력Article Published on 2022-11-302022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibodies antibody B.1.1.7 B.1.351 B.1.617.2 B.1.621 binding binding activity carried conserved convalescent patient coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 determined by domain ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated Evidence Immune escape immune protection mAb mAbs MERS MERS-CoV Middle East Middle East respiratory syndrome Middle East respiratory syndrome Coronavirus molecular monoclonal antibodies monoclonal antibody N Terminal N terminal domain NAbs Neutralization assay neutralization assay. Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody NTD P.1 Protein pseudo-virus RBD Receptor binding domain reported Research respiratory Result S protein S proteins S2 protein S2 subunit SARS-CoV SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 S SARS-CoV-2 S2 SARS-CoV-2 WT Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus significantly specific antibodies subunit target targets terminal Vaccine design variant variants wild-type [DOI] 10.1080/21645515.2022.2055373 PMC 바로가기 [Article Type] Article
An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunizationArticle Published on 2022-11-052022-11-15 Journal: International journal of pharmaceutics [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] addition Antigen antigens applied approach approaches binding affinity circumvent complementary COVID-19 COVID-19 pandemic Delta Diseases evaluated functional fusion strategy generate immunization introduced lack Lipid Lipid nanoparticle (LNP) LNP mAb mAbs Membrane proteins methodology mice Modified mRNA monoclonal antibodies monoclonal antibody neutralize Neutralizing Neutralizing activity posttranslational modification Prophylactic Protein RBD Receptor binding domain SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 spike SARS-CoV-2 virus SARS-CoV-2. serum serum antibody several variants therapeutic drug Treatment Vaccines variants [DOI] 10.1016/j.ijpharm.2022.122256 PMC 바로가기